Mochida Faces Up To Hard Times

30 September 1998

Mochida Pharmaceutical of Japan has announced steps to combat itssignificant slowdown in business, including the reduction of 175 jobs to 2,000 by the end of 2000. However, the firm intends to maintain its number of sales reps (currently 800), though it plans to become more selective about the visits they make, according to the Nikkei Industrial Daily. Mochida is looking to increase the share of the top dozen wholesalers in Japan it deals with, of which there are 80, to 60%-70% from 50% at present. The firm says the refocusing of its sales strategy is meant to make the most of available resources, adding that it is unlikely to meet targeted sales of 63 billion yen ($463.1 million) this fiscal year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight